Evidence map›Paper›PMID 37175467›Full record

ArticleInternational journal of molecular sciences2023

An In Vitro Approach to Model EMT in Breast Cancer.

Lorenz Isert, Aditi Mehta, Gabriele Loiudice, Altea Oliva, Andreas Roidl, Olivia M Merkel

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Fumiquinazolines F and G from the FungusInternational journal of molecular sciences · 2025
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Factors Determining Epithelial-Mesenchymal Transition in Cancer Progression.International journal of molecular sciences · 2024
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lorenz IsertPharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-Universität München, Butenandtstr. 5-13, 81377 Munich, Germany.
Aditi MehtaPharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-Universität München, Butenandtstr. 5-13, 81377 Munich, Germany.
Gabriele LoiudicePharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-Universität München, Butenandtstr. 5-13, 81377 Munich, Germany.
Altea OlivaPharmaceutical Biotechnology, Ludwig-Maximilians-Universität München, Butenandtstr. 5-13, 81377 Munich, Germany.
Andreas RoidlPharmaceutical Biotechnology, Ludwig-Maximilians-Universität München, Butenandtstr. 5-13, 81377 Munich, Germany.
Olivia M MerkelPharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-Universität München, Butenandtstr. 5-13, 81377 Munich, Germany.ORCID 0000-0002-4151-3916
Ludwig-Maximilians-Universität München · DE

Funding

Center for NanoScience Pilot GrantEuropean Resuscitation Council ERC-2014-StG - 637830NanoInitiative Munich Pilot Grant
6 · The paper itself

Abstract

During the progression from ductal carcinoma in situ (DCIS) to invasive breast cancer (IBC), cells must overcome the physically restraining basement membrane (BM), which compartmentalizes the epithelium from the stroma. Since the extracellular matrix (ECM) of the epithelial and stromal compartments are biochemically and physically distinct from one another, the progression demands a certain degree of cellular plasticity for a primary tumor to become invasive. The epithelial-to-mesenchymal transition (EMT) depicts such a cell program, equipping cancer cells with features allowing for dissemination from the epithelial entity and stromal invasion at the single-cell level. Here, the reciprocal interference between an altering tumor microenvironment and the EMT phenotype was investigated in vitro. BM-typical collagen IV and stroma-typical collagen I coatings were applied as provisional 2D matrices. Pro-inflammatory growth factors were introduced to improve tissue mimicry. Whereas the growth on coated surfaces only slightly affected the EMT phenotype, the combinatorial action of collagen with growth factor TGF-β1 induced prominent phenotypic changes. However, EMT induction was independent of collagen type, and cellular accessibility for EMT-like changes was strongly cell-line dependent. Summarizing the entire body of data, an EMT-phenotyping model was used to determine cellular EMT status and estimate EMT-like changes. The miR200c-mediated reversion of mesenchymal MDA-MB-231 cells is reflected by our EMT-phenotype model, thus emphasizing its potential to predict the therapeutic efficacy of EMT-targeting drugs in the future.

Indexed as

Carcinoma, Intraductal, NoninfiltratingCell LineCell Line, TumorCell MovementCollagen Type ICollagen Type IVEpithelial-Mesenchymal TransitionHumansPhenotypeTumor MicroenvironmentCollagen Type ICollagen Type IVbreast cancercollagen coatingsEMTEMT-phenotypingshape factorstumor microenvironment

Identifiers

PMID37175467
PMCPMC10177865
OpenAlexW4366826473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.